Humedix, a subsidiary of Huons Group, said it received approval for three of its hyaluronic acid (HA) filler products -- Elravie Premier Soft-L, Elravie Premier Deep Line-L, and Revolline Hara-L (export name: Charmifil-Mild) – from the Thai Food and Drug Administration.

These products will be distributed in Thailand by its local partner, MnB Thai, an aesthetic-specialized distributor with a network of over 1,500 hospitals and clinics across the country. Through this partnership and strategic marketing efforts, Humedix expects to rapidly increase its market share in Thailand.

Elravie Premier and Revolline are premium Korean filler brands that incorporate Humedix's proprietary high-purity and cross-linking HA production technology. These fillers comply with the European Pharmacopoeia (EP) standards and utilize the same aseptic pharmaceutical-grade HA raw materials registered under the Korean Drug Master File (DMF).

The Elravie Premier line features Humedixw’s exclusive Hi-B (High Viscoelasticity-Hybrid) technology, ensuring product stability and long-lasting viscoelastic properties. The product has already earned regulatory approvals in the European Union (CE), China’s National Medical Products Administration (NMPA), and Russia’s Federal Service for Surveillance in Healthcare (RZN). With the latest Thai approval, Elravie Premier is now exported to 19 countries, including China and Brazil, and continues to see growing sales both domestically and internationally.

Revolline marks its first overseas market entry with the Thai approval. The Revolline Hara filler is designed to maximize the benefits of monophasic and biphasic fillers, featuring high elasticity and minimal BDDE (cross-linking agent) residue. Humedix developed the filler using its proprietary HiVE (high viscoelasticity) technology and multiple refinement processes to enhance cross-linking efficiency.

Moving forward, Humedixplans to expand Revolline’s registration to additional international markets, reinforcing its global presence alongside the well-established Elravie Premier brand.

"We are delighted to showcase the superior quality and technology of Humedix’s HA fillers through this approval in Thailand,” Humedix CEO Kim Jin-hwan said. “We remain committed to expanding our global influence and will continue to focus on strengthening our presence in international markets."